健帆生物(300529)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300529 健帆生物

已收盘 05-17 15:00:00

{"stockData":{"symbol":"300529","market":"SZ","secType":"STK","nameCN":"健帆生物","latestPrice":28.93,"timestamp":1715929401000,"preClose":28.8,"halted":0,"volume":5614133,"delay":0,"floatShares":521000000,"shares":808000000,"eps":0.6498,"marketStatus":"已收盘","marketStatusCode":5,"change":0.13,"latestTime":"05-17 15:00:00","open":28.87,"high":28.98,"low":28.61,"amount":162000000,"amplitude":0.0128,"askPrice":28.93,"askSize":17,"bidPrice":28.92,"bidSize":203,"shortable":0,"etf":0,"ttmEps":0.6498,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716168600000},"adr":0,"adjPreClose":28.8,"symbolType":"stock","openAndCloseTimeList":[[1715909400000,1715916600000],[1715922000000,1715929200000]],"highLimit":31.68,"lowLimit":25.92,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":807555312,"pbRate":7.48,"roa":"--","roe":"8.97%","epsLYR":0.55,"committee":0.211814,"marketValue":23363000000,"floatMarketCap":15082000000,"peRate":44.521391,"changeRate":0.0045,"turnoverRate":0.0108,"status":0},"requestUrl":"/m/hq/s/300529","defaultTab":"news","newsList":[{"id":"2433744536","title":"5月6日健帆生物涨6.79%，国金国鑫发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433744536","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433744536?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:38","pubTimestamp":1714984694,"startTime":"0","endTime":"0","summary":"证券之星消息，5月6日健帆生物涨6.79%创60日新高，收盘报29.41元，换手率4.45%，成交量23.18万手，成交额6.72亿元。重仓健帆生物的公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为35.76。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为国金国鑫发起A。该公募基金现任基金经理为王小刚。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600015283.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433646014","title":"国金证券：给予健帆生物买入评级，目标价位33.31元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433646014","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433646014?lang=zh_cn&edition=full","pubTime":"2024-05-06 10:46","pubTimestamp":1714963610,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司袁维,何冠洲近期对健帆生物进行研究并发布了研究报告《经营业绩柳暗花明，创新推广拾级而上》，本报告对健帆生物给出买入评级，认为其目标价位为33.31元，当前股价为29.19元，预期上涨幅度为14.11%。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家；过去90天内机构目标均价为36.99。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600005748.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431465460","title":"健帆生物（300529）4月26日主力资金净卖出5764.48万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431465460","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431465460?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:10","pubTimestamp":1714353054,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年4月26日收盘，健帆生物报收于26.15元，上涨12.23%，换手率6.29%，成交量32.81万手，成交额8.36亿元。近5日资金流向一览见下表：健帆生物融资融券信息显示，融资方面，当日融资买入5548.26万元，融资偿还6881.73万元，融资净偿还1333.46万元。健帆生物主营业务：血液灌流相关产品的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900002076.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430223868","title":"健帆生物(300529)3月31日股东户数5.41万户，较上期减少6.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430223868","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430223868?lang=zh_cn&edition=full","pubTime":"2024-04-26 17:26","pubTimestamp":1714123584,"startTime":"0","endTime":"0","summary":"证券之星消息，近日健帆生物披露，截至2024年3月31日公司股东户数为5.41万户，较12月31日减少3551.0户，减幅为6.16%。在医疗器械行业个股中，健帆生物股东户数高于行业平均水平，截至3月31日，医疗器械行业平均股东户数为2.11万户。从股价来看，2023年12月31日至2024年3月31日，健帆生物区间跌幅为0.0%，在此期间股东户数减少3551.0户，减幅为6.16%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600040940.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430824451","title":"4月26日健帆生物涨12.23%，国金国鑫发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430824451","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430824451?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:25","pubTimestamp":1714119943,"startTime":"0","endTime":"0","summary":"证券之星消息，4月26日健帆生物涨12.23%创60日新高，收盘报26.15元，换手率6.29%，成交量32.81万手，成交额8.36亿元。重仓健帆生物的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家；过去90天内机构目标均价为32.13。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为国金国鑫发起A。该公募基金现任基金经理为王小刚。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600035313.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430929822","title":"血液制品概念盘中拉升，健帆生物涨10.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430929822","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430929822?lang=zh_cn&edition=full","pubTime":"2024-04-26 11:20","pubTimestamp":1714101625,"startTime":"0","endTime":"0","summary":"04月26日，血液制品概念盘中拉升，截至11点20分，血液制品概念整体指数上涨1.01%，报758.400点。从个股上来看，该概念的成分股中，健帆生物涨10.73%，同方股份、君正集团、赛伦生物涨幅居前。从资金上来看，截止发稿，血液制品概念概念主力净流入为-5041.32万，其中同方股份受到资金热捧，主力净流入1236.01万；拉长时间线来看，该板块近20日主力资金净流入-1.88亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042611202587e840d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042611202587e840d4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430294647","title":"国金证券：给予健帆生物增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2430294647","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430294647?lang=zh_cn&edition=full","pubTime":"2024-04-26 10:58","pubTimestamp":1714100297,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司袁维,何冠洲近期对健帆生物进行研究并发布了研究报告《一季度业绩恢复高增长，国内外产品研发推进顺利》，本报告对健帆生物给出增持评级，当前股价为25.95元。　　经营分析　　一季度恢复销售增长，血液灌流器产品需求旺盛。2024年Q1公司整体收入实现30%增速，其中血液灌流器、吸附器产品实现销售收入6.92亿元，同比增长85.51%，核心产品需求显著恢复。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600025780.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430237650","title":"图解健帆生物一季报：第一季度单季净利润同比增44.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430237650","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430237650?lang=zh_cn&edition=full","pubTime":"2024-04-26 01:46","pubTimestamp":1714067211,"startTime":"0","endTime":"0","summary":"证券之星消息，健帆生物2024年一季报显示，公司主营收入7.44亿元，同比上升30.0%；归母净利润2.85亿元，同比上升44.9%；扣非净利润2.71亿元，同比上升42.74%；负债率44.76%，投资收益252.83万元，财务费用47.64万元，毛利率78.68%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600002352.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430238761","title":"健帆生物(300529.SZ)发布一季度业绩，净利润2.85亿元，同比增长44.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430238761","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430238761?lang=zh_cn&edition=full","pubTime":"2024-04-25 23:30","pubTimestamp":1714059030,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健帆生物(300529.SZ)披露2024年第一季度报告，报告期公司实现营收7.44亿元，同比增长30%;归母净利润2.85亿元，同比增长44.9%;扣非净利润2.71亿元，同比增长42.74%。基本每股收益0.3512元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1110932.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430284928","title":"健帆生物最新公告：一季度净利润2.85亿元 同比增长44.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430284928","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430284928?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:19","pubTimestamp":1714054788,"startTime":"0","endTime":"0","summary":"健帆生物公布2024年一季度报告，报告期营业收入7.44亿元，同比增长30.00%；归属于上市公司股东的净利润2.85亿元，同比增长44.90%。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500046060.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2424817316","title":"健帆生物(300529.SZ)耗资约5亿元完成回购3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2424817316","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2424817316?lang=zh_cn&edition=full","pubTime":"2024-04-03 20:21","pubTimestamp":1712146860,"startTime":"0","endTime":"0","summary":"健帆生物(300529.SZ)发布公告，截至2024年4月3日，公司通过回购专用证券账户以集中竞价交易方式累计回购公司股份2424.29万股，占公司总股本的3%，本次回购股份的最高成交价为24.93元/股，最低成交价为15.89元/股，成交金额约为5亿元(不含交易费用)。至此，公司本次回购方案实施完成。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-03/doc-inaqqitn5915340.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-03/doc-inaqqitn5915340.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419295627","title":"健帆生物(300529.SZ)血液透析类医用耗材中选河南省集中带量采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2419295627","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2419295627?lang=zh_cn&edition=full","pubTime":"2024-03-14 17:11","pubTimestamp":1710407460,"startTime":"0","endTime":"0","summary":"健帆生物(300529.SZ)发布公告，公司及全资子公司珠海健帆血液净化科技有限公司(简称“健帆血液净化”)参加了河南省血液透析类医用耗材省际联盟带量采购投标工作。根据河南省医疗保障局近日发布的《血液透析类医用耗材省际联盟采购公告(七)》，公司及健帆血液净化的高通量血液透析器、非高通量血液透析器、血液透析管路产品中选本次集中带量采购。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-14/doc-inanhvcq7677174.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-14/doc-inanhvcq7677174.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2404847527","title":"健帆生物(300529.SZ)发预减，预计2023年度净利润3.4亿元~4.9亿元，同比暴跌62%~45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2404847527","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2404847527?lang=zh_cn&edition=full","pubTime":"2024-01-19 17:41","pubTimestamp":1705657260,"startTime":"0","endTime":"0","summary":"健帆生物发布2023年度业绩预告，公司预计2023年度归属于上市公司股东的净利润3.4亿元~4.9亿元，同比下降62%~45%;扣除非经常性损益后的净利润3.12亿元~4.62亿元，同比下降62%~44%。报告期内，受行业需求波动、公司部分产品价格同比下降等因素影响，本期营业收入和产品毛利率同比下降。为加大对人才的激励，公司在报告期内连续实施两期员工持股计划，股份支付费用同比显著增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-19/doc-inaeafvy0587364.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-19/doc-inaeafvy0587364.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2016-08-02","address":"广东省珠海市香洲区高新区科技六路98号","stockEarnings":[{"period":"1week","weight":-0.0126},{"period":"1month","weight":0.2661},{"period":"3month","weight":0.4133},{"period":"6month","weight":0.26},{"period":"1year","weight":0.0226},{"period":"ytd","weight":0.3014}],"companyName":"健帆生物科技集团股份有限公司","boardCode":"AI0035","perCapita":"9640股","boardName":"专用设备制造业","registeredCapital":"80755万元","compareEarnings":[{"period":"1week","weight":-0.0002},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.1005},{"period":"6month","weight":0.0326},{"period":"1year","weight":-0.0435},{"period":"ytd","weight":0.0602}],"survey":"　　健帆生物科技集团股份有限公司主要从事血液灌流相关产品及设备的研发、生产与销售。主要产品有血液灌流器、血液净化设备、血液透析粉液产品。公司系国家高新技术企业，“高性能血液净化医用吸附树脂的创制”项目曾获“2009 年国家科技进步二等奖”，承担两项“国家重点新产品项目”、三项“国家级火炬计划项目”；被认定为“国家火炬计划重点高新技术企业”。","serverTime":1716089706461,"listedPrice":10.8,"stockholders":"54079人(较上一季度减少6.16%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"健帆生物(300529)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供健帆生物(300529)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"健帆生物,300529,健帆生物股票,健帆生物股票老虎,健帆生物股票老虎国际,健帆生物行情,健帆生物股票行情,健帆生物股价,健帆生物股市,健帆生物股票价格,健帆生物股票交易,健帆生物股票购买,健帆生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"健帆生物(300529)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供健帆生物(300529)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}